Welcome to our dedicated page for Ensysce Biosciences news (Ticker: ENSC), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences stock.
Ensysce Biosciences Inc (NASDAQ: ENSC): Redefining Pain Management with Safer Prescription Drugs
Ensysce Biosciences Inc, headquartered in San Diego, CA, is a clinical-stage pharmaceutical company pioneering innovative solutions to address the opioid crisis. Leveraging its proprietary drug delivery platforms, Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR™), the company is developing tamper-proof, abuse-resistant opioids designed to minimize the risks of misuse and overdose. These technologies represent a breakthrough in pain management, offering safer alternatives for patients suffering from severe acute and chronic pain.
Core Technology Platforms: TAAP™ and MPAR™
Ensysce's TAAP™ platform chemically modifies opioids to remain inactive until activated by trypsin in the small intestine, mitigating risks associated with non-oral routes of abuse such as snorting or injecting. The MPAR™ platform builds on TAAP™ by incorporating overdose protection, effectively "switching off" the release of the opioid when consumed in excessive quantities. Together, these platforms address two critical public health challenges: opioid abuse and accidental overdose.
Clinical Development Pipeline
The company’s lead product candidates include PF614, an extended-release oxycodone prodrug, and PF614-MPAR, which integrates overdose protection. PF614 has demonstrated bioequivalence to OxyContin® in clinical studies, positioning it for a streamlined regulatory approval pathway under the FDA's 505(b)(2) process. PF614-MPAR, which received Breakthrough Therapy designation from the FDA, has shown promising interim results in clinical trials, confirming its ability to prevent overdose while maintaining effective pain relief.
Strategic Partnerships and Intellectual Property
Ensysce has secured partnerships with leading specialty drug manufacturers to scale production and streamline the transition from clinical trials to commercialization. The company also benefits from a robust intellectual property portfolio, covering a wide array of prescription drug compositions, ensuring global protection for its innovative platforms.
Addressing a Critical Public Health Crisis
The opioid epidemic remains a significant challenge, with millions of Americans affected by opioid misuse and overdose annually. Ensysce’s solutions aim to reduce these human and economic costs by offering safer prescription drugs that balance efficacy with safety. The company’s technologies not only address abuse deterrence but also provide much-needed innovation in a pharmaceutical segment that has seen limited advancements in recent decades.
Market Position and Competitive Landscape
Operating within the pharmaceutical industry’s pain management segment, Ensysce differentiates itself through its focus on abuse-deterrent and overdose-protected opioids. While traditional opioids and emerging treatments like NaV1.8 inhibitors address pain relief, Ensysce’s unique approach targets the dual challenges of efficacy and safety, positioning it as a critical player in the fight against opioid misuse.
Commitment to Innovation and Patient Safety
Ensysce Biosciences is committed to transforming pain management by creating prescription drugs that prioritize patient safety without compromising on effectiveness. Through its groundbreaking technology platforms, the company is poised to make a significant impact on public health by addressing the dual crises of opioid abuse and inadequate pain relief options.
Ensysce Biosciences (NASDAQ:ENSC) reported positive progress in its clinical trial evaluating PF614-MPAR for overdose protection. The study demonstrated that a 100mg dosage provides overdose protection when consumed above prescribed amounts, with successful enrollment in the highest dosing cohort of 5x the 100mg dose unit.
The trial has shown adverse events, confirming the favorable safety profile of PF614 and PF614-MPAR as novel opioids for severe pain treatment. The FDA granted Breakthrough Therapy designation to PF614-MPAR in 2024, recognizing its unique position as an opioid with oral overdose protection.
The company believes its products will address an unmet need in severe and chronic pain management, particularly following recent FDA approval of NaV1.8 inhibitors for moderate pain treatment.
Ensysce Biosciences (NASDAQ:ENSC) announced positive interim data from its Phase 1b clinical trial (PF614-MPAR-102) evaluating PF614-MPAR for overdose protection. The study demonstrated that the 100 mg dosage form provides significant overdose protection when taken in greater-than-prescribed doses.
The trial showed subjects receiving the MPAR product had a significantly lower (p=0.0019) total maximum blood concentration of oxycodone compared to PF614 alone. At single 100 mg doses, both formulations showed no difference in Cmax values (p=0.523), with no unexpected adverse events reported.
The study follows PF614-MPAR's FDA Breakthrough Therapy designation in 2024 and a $14 million multi-year NIDA award. The trial will continue with final cohorts in Part 1, followed by food effect studies in Part 2, and repeat dosing evaluation in Part 3.
Ensysce Biosciences (NASDAQ:ENSC) reported significant progress in 2024 for its innovative pain relief solutions. Key achievements include receiving FDA Breakthrough Therapy designation for PF614-MPAR, an opioid with overdose protection, and advancing their lead product PF614, a tamper-resistant extended-release oxycodone.
The company completed an End of Phase 2 FDA meeting for PF614 and plans to commence Phase 3 trials in Q2 2025. They also initiated a Phase 1b study for PF614-MPAR and selected PF9001 as their lead candidate for Opioid Use Disorder treatment.
Financial highlights include securing $4.7 million through a warrant inducement in February, $5 million in August, and receiving a $14 million NIH grant for PF614-MPAR development. The company aims to submit a New Drug Application for PF614 in 2026.
Ensysce Biosciences (NASDAQ:ENSC) has regained full compliance with Nasdaq listing requirements. The company received notice on December 20, 2024, confirming its compliance with the minimum bid price requirement (Rule 5550(a)(2)). This follows their previous compliance with the stockholders' equity requirement (Rule 5550(b)(1)). Having met all requirements outlined in the Nasdaq Hearings Panel decision from November 5, 2024, ENSC will continue trading on The Nasdaq Capital Market.
Ensysce Biosciences (NASDAQ:ENSC) has secured a commitment for future supply of GMP nafamostat from Aurore Life Sciences. This agreement is important for PF614-MPAR, the company's overdose protection drug product, as nafamostat is a vital component. The partnership allows Ensysce to reference Aurore's Drug Master File and fully secures the supply chain for PF614-MPAR, which is currently advancing through clinical development. Additionally, the company has initiated other programs using nafamostat as a single agent for various indications, which will also benefit from this supply agreement.
Ensysce Biosciences (NASDAQ:ENSC) has announced a strategic partnership with a leading specialty drug manufacturer for the development and commercial launch of PF614 and PF614-MPAR drug products. The partnership includes a $10 million commitment and involves the manufacturer taking an equity position in Ensysce.
The collaboration will provide Ensysce with clinical trial material, drug products for regulatory submissions, and initial commercial batches. The partner will handle the complete manufacturing process, including packaging, labeling, and shipment. This partnership secures key Chemistry Manufacturing and Control (CMC) elements for the New Drug Application (NDA) submission, supporting the company's goal of achieving regulatory approval for their innovative pain relief solutions.
Ensysce Biosciences (NASDAQ:ENSC) has announced a 1-for-15 reverse stock split effective December 6, 2024, at 12:01 a.m. Eastern Time. The company's stock will continue trading under the symbol 'ENSC' with a new CUSIP number 293602 504.
The primary purpose of this reverse split is to increase the bid price of the company's common stock to meet Nasdaq's minimum bid requirement of $1.00 per share for continued listing. Every 15 shares will be automatically combined into 1 share, with fractional shares rounded up to the nearest whole number. Stockholders' proportional ownership will remain unchanged, except for minor adjustments due to fractional share treatment.
Ensysce Biosciences (NASDAQ:ENSC) has initiated dosing in the PF614-MPAR-102 study, marking a significant milestone for its breakthrough therapy-designated opioid drug. The trial aims to evaluate the pharmacokinetics of oxycodone and PF614 when co-administered with nafamostat. The study received a $14 million multi-year award from NIDA and expects early interim data in Q1 2025. The three-part trial will assess the full dosage range, food effects, and conduct multi-ascending dose studies of PF614-MPAR, which is designed to reduce deliberate and accidental overdoses in severe pain treatment.
Ensysce Biosciences (NASDAQ:ENSC) reported Q3 2024 financial results, highlighting a $14 million NIH grant for PF614-MPAR development and the initiation of its second clinical trial. The company submitted a pivotal Phase 3 protocol for PF614 to FDA review. Cash position improved to $4.2 million from $1.1 million at 2023-end. Q3 showed net income of $0.7 million, compared to a $2.7 million loss year-over-year, primarily due to increased federal grant funding of $3.4 million. R&D expenses decreased to $1.7 million from $1.9 million, while G&A expenses slightly declined to $1.1 million.
Ensysce Biosciences (NASDAQ:ENSC) has received a positive determination from Nasdaq regarding its listing status. The company has been granted an extension until November 14, 2024, to demonstrate compliance with the equity requirement by filing its Form 10-Q. Additionally, Nasdaq extended the deadline to December 19, 2024, for meeting the Minimum Bid Price requirement and other applicable conditions to maintain its listing on The Nasdaq Capital Market.
FAQ
What is the current stock price of Ensysce Biosciences (ENSC)?
What is the market cap of Ensysce Biosciences (ENSC)?
What does Ensysce Biosciences Inc do?
What are TAAP™ and MPAR™ technologies?
What are Ensysce's lead drug candidates?
How does Ensysce address the opioid crisis?
What makes Ensysce's approach unique?
What is the significance of FDA Breakthrough Therapy designation for PF614-MPAR?
What markets does Ensysce target?
Who are Ensysce's competitors?
What partnerships has Ensysce formed?
How does Ensysce fund its operations?
